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Summary: Response-adaptive designs allow the randomization probabilities to change during the 
course of a trial based on cumulated response data so that a greater proportion of patients can be 
allocated to the better performing treatments. A major concern over the use of response-adaptive 
designs in practice, particularly from a regulatory viewpoint, is controlling the type I error rate. In 
particular, we show that the naïve z-test can have an inflated type I error rate even after applying a 
Bonferroni correction. Simulation studies have often been used to demonstrate error control but do not 
provide a guarantee. In this paper, we present adaptive testing procedures for normally distributed 
outcomes that ensure strong familywise error control by iteratively applying the conditional invariance 
principle. Our approach can be used for fully sequential and block randomized trials and for a large 
class of adaptive randomization rules found in the literature. We show there is a high price to pay in 
terms of power to guarantee familywise error control for randomization schemes with extreme 
allocation probabilities. However, for proposed Bayesian adaptive randomization schemes in the 
literature, our adaptive tests maintain or increase the power of the trial compared to the z -test. We 
illustrate our method using a three-armed trial in primary hypercholesterolemia.This article is protected 
by copyright. All rights reserved 
 
Key words: Bayesian methods; Closed testing; Multiple comparisons; Response-adaptive 
randomization; Type I error. 
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Familywise error control in multi-armed response-adaptive trials 1
1. Introduction
Clinical trials typically randomize patients using a fixed randomization scheme, where the
probabilities of assigning patients to the experimental treatments and control are pre-specified
and constant. A common method is to simply use equal randomization to the different arms
of the trial. However, such randomization schemes can mean that a substantial proportion
of the trial participants will continue to be allocated to treatments that are not the best
available, even if interim data indicates that one treatment is likely to be superior. Response-
adaptive trials address this concern by adaptively changing the randomization probabilities,
so that a greater proportion of patients are allocated to the treatment arm which has a better
performance based on the cumulated response data.
Many classes of response-adaptive randomization (RAR) schemes have been proposed for
binary outcomes, and there is also a growing interest in RAR for continuous responses.
In Web Appendix A, we present an overview of multi-arm RAR schemes described in the
literature. Our focus in this paper is on normally distributed outcomes, which are encountered
in a number of clinical trials. Indeed, 23 out of the 59 trials identified in a review of multi-arm
trials by Wason et al. (2014) had a continuous outcome.
Despite the extensive literature on RAR, relatively few clinical trials have actually used
such schemes in practice. A current example is the ongoing I-SPY 2 trial (Park et al.,
2016), which screens drugs in neoadjuvant breast cancer and uses RAR as part of its design.
One of the key concerns over using RAR, particularly from a regulatory perspective, is
ensuring that the type I error rate is controlled. In a multi-arm trial, multiple hypotheses
are tested simultaneously by design, which leads to a multiple testing problem. To account
for this, testing procedures are used that guarantee strong control of the familywise error
rate (FWER), which ensures the maximum probability of making at least one type I error
is controlled. For confirmatory trials in particular, demonstrating strong control of the
This article is protected by copyright. All rights reserved
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2 Biometrics, 000 2019
FWER is often required by regulators (European Medicines Agency, 2002; Food and Drug
Administration, 2018).
For response-adaptive trials, a rigorous proof of FWER control for a particular design
is difficult given the complexities of the treatment allocation process. Hence error control
has typically either been demonstrated through simulation studies, or by exploiting the
asymptotic structure of the adaptive randomization procedure (Hu and Rosenberger, 2006;
Zhu and Hu, 2010). However, neither method provides a guarantee of FWER control,
particularly with small sample sizes. Another possibility is the use of (re)-randomization
tests to preserve type I error (Simon and Simon, 2011), which we return to in Section 6.
Gutjahr et al. (2011) showed how to achieve strong control of the FWER for normally
distributed outcomes in a two-stage design incorporating RAR in the first stage. However,
our focus is on general response-adaptive trials, without the necessity of restricting to two
stages or having a final stage of equal randomization.
In this paper, we show how to guarantee strong control of the FWER for both fully
sequential and block randomized response-adaptive trials, for a large class of adaptive ran-
domization rules. Our proposed procedure works by reweighting the usual z-statistic through
an iterative application of the conditional invariance principle. The resulting test statistic
can then be used to test the null hypothesis that a treatment is superior to the control.
The rest of the paper is organised as follows. In Section 2, we describe the proposed
method for fully sequential response-adaptive trials with a fixed allocation to the control.
This method is then modified for block randomized response-adaptive trials in Section 3,
for both a fixed or adaptive control allocation. Simulation studies for the proposed methods
are presented in Section 4, and Section 5 gives a case study based on a trial in primary
hypercholesterolemia. We conclude with a discussion in Section 6. All proof details can be
found online in the Supporting Information section.
This article is protected by copyright. All rights reserved
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Familywise error control in multi-armed response-adaptive trials 3
2. Fully sequential response-adaptive trials
2.1 Trial setting
Suppose a trial is conducted to test t > 1 experimental treatments against a common control,
using the following design. A total of n patients are allocated to the experimental treatments,
and n0 patients are allocated to the control, where n0 and n are fixed in advance. Patients
are allocated to the different experimental treatments using RAR, where we assume that
the randomization rule does not depend on the control information. We also assume the
allocation to the control is fixed; that is, the probability of assigning a patient to the control is
pre-specified and constant. Maintaining allocation to the control is recommended by the Food
and Drug Administration (2018), since it best maintains the power of the trial, and helps
address the concern about changing patient characteristics over the course of the trial.
The RAR for the experimental treatments starts with a burn-in period B, which uses fixed
randomization to allocate ri > 0 patients to the ith treatment (i = 1, . . . , t), with the ri again
fixed in advance. Hence a total of r =
∑t
i=1 ri patients are allocated to the experimental
treatments during the burn-in period. Let ak denote the treatment allocation for the kth
experimental patient (k = 1, . . . , n), where ak = i if the kth patient is allocated to the ith
treatment. The allocation ak can depend on the data (i.e. the allocations and outcomes)
observed up to patient k − 1, as well as any external information available at that time.
Also let Xk denote the efficacy outcome for the kth patient, while X0j denotes the efficacy
outcomes for the jth patient on the control (j = 1, . . . , n0) where
X0j ∼ N(µ, σ2), Xk |ak=i ∼ N(µ+ δi, σ2)
The variance σ2 is assumed known and, without loss of generality, we set σ2 = 1. Here δi
represents the incremental benefit of treatment i compared to the control, and is the param-
eter of interest. Finally, let ni denote the total number of allocations to the ith experimental
treatment (including the burn-in period) and nI =
∑
i∈I ni.
This article is protected by copyright. All rights reserved
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4 Biometrics, 000 2019
2.2 Hypothesis testing
The elementary null hypotheses are Hi : δi = 0 against the one-sided alternatives H¯i : δi > 0.
We discuss the case when Hi : δi 6 0 at the end of Section 2.5. One general method to control
for multiple testing is to use the closure principle (Marcus et al., 1976) and consider all
intersection hypotheses HI , where I ⊆ {1, . . . , t}. To strongly control the FWER, we reject
an elementary null hypothesis Hi if we also reject every HI with i ∈ I using a local level-α
test. Hence we need to define a valid level-α test for all the intersection hypotheses HI . The
na¨ıve z-test for HI , which does not take into account the RAR used in the trial, rejects HI
if the test statistic
TI =
n∑
k=1
(
1{ak∈I}
Xk
nI
)
−
n0∑
j=1
X0j
n0
is greater than zα (1/nI + 1/n0)
1/2, where zα is the (1− α) standard normal quantile.
As an alternative to using the closure principle with the test statistic above, one could
simply use the Bonferroni correction, or a step-up/step-down procedure such as the Holm
procedure. These would only involve calculating test statistics for the t elementary null
hypotheses, i.e. calculating TI for I = {i} (i = 1, . . . , t). Hence we present the methodology
assuming the closure principle will be used, with the Bonferroni and Holm procedures
considered as special cases. We return to this issue in Section 4.
2.3 Inflation of the familywise error rate
Since the z-test ignores the adaptive randomization used, it is possible to inflate the FWER.
As an example, consider the following adaptive randomization scheme for t = 2 treatments:
ak+1 =

2 if
∑k
j=1(1{aj=1}
Xj
n1k
) > 0.5
1 otherwise
where n1k =
∑k
j=1 1{aj=1}. This can be viewed as implementing early stopping for efficacy
for treatment 1, which is not taken into account using the na¨ıve z-test.
This article is protected by copyright. All rights reserved
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Familywise error control in multi-armed response-adaptive trials 5
We ran a simulation study to calculate the type I error rate using the above randomization
scheme. We set α = 0.05, n0 = n = 60, r1 = r2 = 5 and the true treatment means
µ = 0, δ1 = 0, δ2 = 1. The type I error rate as averaged over 10
5 simulations is 10.4%, more
than double the nominal 5% level. We subsequently refer to allocation rules of this type as
‘type I error inflator’ rules (which clearly would never be used in practice).
2.4 Auxiliary design
Working with the actual design of the trial is difficult because RAR affects the distribution
of the usual z-test statistics. Hence for each HI we introduce a simpler design, called the
auxiliary design, for which we do know the distribution. The actual trial design can then be
viewed as a series of data-dependent modifications of the auxiliary design, where we account
for the modifications using the conditional invariance principle. The auxiliary designs are
purely hypothetical, and are only used to construct the modified tests for the actual design.
As well, the allocations in the auxiliary designs are fixed before the start of the actual trial.
The auxiliary design for hypothesis HI is as follows. As in the actual design, a total
of n patients are allocated to the experimental treatments, and n0 patients are allocated
to control. The allocations and responses to the control treatment are the same as the
actual design. For the patients allocated to the experimental treatments, the auxiliary design
starts with a burn-in period B with r patients that is identical to the actual design. The
subsequent n− r− 1 allocations are given by a fixed sequence (br+1, . . . , bn−1), which can be
chosen arbitrarily. The final allocation bn must be to one of the treatments in I.
These allocations can be considered as an approximation, made before the trial begins, to
what we could reasonably expect the actual allocations to be. Assuming clinical equipoise,
there is no way of knowing a priori that the probability of assignment to a treatment will
be higher or lower than that for any other treatment (given some adaptive randomization
scheme). Hence randomizing equal numbers of patients to each treatment for the auxiliary
This article is protected by copyright. All rights reserved
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6 Biometrics, 000 2019
design is the natural choice for trials where there is genuine uncertainty over the effectiveness
of the different treatments. We return to these issues in Section 6.
For the auxiliary design, let Yk denote the efficacy outcome for the kth patient under
the auxiliary design (k = 1, . . . , n), where Yk = Xk for k = 1, . . . , r by design. Also let
n′i =
∑n
j=1 1{bj=i} denote the total number of allocations to the ith experimental treatment,
and mi,k =
∑n
j=k 1{bj=i} denote the total number of allocations to the ith treatment for
patients (k, k + 1, . . . , n). We then define n′I =
∑
i∈I n
′
i and mI,k =
∑
i∈I mi,k. Under the
auxiliary design, n′i is fixed for all i, and hence under HI , the usual z-statistic
T ′I =
n∑
k=1
(
1{bk∈I}
Yk
n′I
)
−
n0∑
j=1
X0j
n0
is normally distributed with mean zero and variance (1/n′I + 1/n0). Hence we reject HI if T
′
I
is greater than zα (1/n
′
I + 1/n0)
1/2.
2.5 Adaptive test statistic
Adaptive designs, such as the trial being considered, follow a common conditional invariance
principle in order to control the type I error rate (Brannath et al., 2007). For our response-
adaptive trial in question, we apply the conditional invariance principle sequentially, where
each step considers the next patient recruited into the trial. Below we give the test statistic
for testing hypothesis HI under the actual design, given that the allocation is fully sequential.
Theorem 1: Under HI , the following test statistic is normally distributed with mean 0
and variance (1/n′I + 1/n0)
T˜I =
n∑
k=1
(
1{ak∈I}
Xk
w
(I)
k
)
−
n0∑
j=1
X0j
w
(0)
n,j
The weights w
(I)
k and w
(0)
n,j for the efficacy outcomes are calculated recursively based on the
number of allocations to the experimental treatments and the control, with full details and
the proof of Theorem 1 provided in Web Appendix B.
This article is protected by copyright. All rights reserved
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Familywise error control in multi-armed response-adaptive trials 7
Using Theorem 1, we reject HI if T˜I is greater than zα (1/n
′
I + 1/n0)
1/2. In practice, to
keep the weights as close to the natural weight n0 for as many of the control observations
as possible, we recommend setting m0,1 = n0 − 1 and m0,2 = 1, as used for the simulation
studies in Section 4.1. As a simple illustration of how the weights change over the course of a
trial, consider testing t = 2 experimental treatments. We set α = 0.05, n0 = 10, n = 11 and
r1 = r2 = 1. Suppose we have no a priori reason to favour one treatment over the other, and
so we simply choose the auxiliary design to be an equal randomization of the two treatments:
b = 1 2 2 1 2 2 1 1 2 1 ∗
Here the vertical line indicates where the burn-in period ends, and the * represents the
allocation for bn, which by design must satisfy bn ∈ I. We set m0,1 = 9 and m0,2 = 1, so that
w
(0)
1 = · · · = w(0)9 . Table 1 below shows how the weights change over the course of a trial for
an actual allocation a that is similar to the auxiliary design b. Further examples for a variety
of actual allocations a can be found in Web Appendix C.
[Table 1 about here.]
In all of the scenarios that we have investigated, the weights w
(I)
k for the experimental
treatments have been positive (although we cannot rule out the possibility of having negative
or imaginary weights). Hence in these cases, the test procedure also controls the FWER
for the composite null hypotheses Hi : δi 6 0. To see this, suppose the elementary null
hypotheses are H∗i : δi = δ
∗
i < 0. Under H
∗
I , we can rewrite the distribution of the responses
X∗k as Xk + δ
∗
k, where Xk ∼ N(0, 1). Hence under H∗I
pr(T˜ ∗I > c) = pr
(
T˜I > c−
n∑
k=1
1{ak∈I}
δ∗k
w
(I)
k
)
< pr(T˜I > c)
where T˜ ∗I and T˜I are the adaptive test statistics for H
∗
I and HI respectively.
This article is protected by copyright. All rights reserved
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8 Biometrics, 000 2019
3. Block randomized response-adaptive trials
3.1 Trial setting
It may not be feasible or desirable to randomize patients one-by-one in a fully sequential
manner. Instead one can use block randomization, where after the burn-in period B, patients
are adaptively randomized to the experimental treatments in blocks of size (d1, . . . , dJ) over J
stages, with
∑J
j=1 dj = n. The randomization of the jth block depends on the data up to
block (j−1), as well as any external information available at the time. The allocation to the
control is again assumed to be fixed throughout the trial.
Due to the block structure of the trial, we can relax the assumption that the randomization
rule used for the experimental treatments does not depend on the control information. This is
achieved by splitting up the n0 patients allocated to the control into blocks. More explicitly,
suppose that during the burn-in period, r0 > 0 patients are allocated to the control, where r0
is fixed in advance. Subsequently, in the jth block, d0j patients are allocated to the control,
where
∑J
j=1(r0 + d0j) = n0. We assume that for the final block d0J > 1. The response-
adaptive randomization at block l may now depend on the control information available at
the end of block (l − 1); that is, the outcome data available from the first ∑l−1j=1(r0 + d0j)
patients allocated to the control.
To control the FWER, we can modify the approach in Section 2 to account for the block
structure. As before, we have an auxiliary design for the patients on the experimental treat-
ments, but now in step l of the process the actual design is a data-dependent modification of
all the allocations for the patients in block l. Hence the weights for the observations in each
block will be the same, and are updated block-by-block. Full details of the auxiliary design
and the resulting adaptive test statistic T˜I can be found in Web Appendix D.
This article is protected by copyright. All rights reserved
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Familywise error control in multi-armed response-adaptive trials 9
3.2 Extension for adaptive control allocations
Thus far, we have assumed that the allocations to the control follow some fixed scheme. We
now relax this assumption in the block-randomized setting. The formula for the adaptive
test statistic T˜I can be found in Web Appendix E. Note that it is possible the procedure will
fail to give a valid test statistic in this setting, as shown in Web Appendix F.3.
4. Simulation studies
As we have already seen in Section 2.3, using the closure principle with the usual z-test does
not strongly control the FWER. An alternative method is to use the Bonferroni correction
on the elementary null hypotheses H1, . . . , Ht. We also consider the Holm procedure, which
is a step-down procedure that is uniformly more powerful than Bonferroni (Holm, 1979). An
advantage of both these procedures is that only t test statistics are calculated, rather than
(2t − 1) test statistics when using the closure principle. This motivates also applying the
Holm procedure to the p-values derived from the adaptive test statistics T˜i for i = 1, . . . , t.
More precisely, we use the adjusted p-values p˜i = 1−Φ((1/n′i + 1/n′0)−1/2 T˜i), instead of the
usual p-values pi = 1− Φ((1/ni + 1/n0)−1/2 Ti) derived from the z-test.
To distinguish between the methods, we call our proposed procedure that uses the closure
principle the ‘adaptive closed test’. Similarly, applying the closure principle to the usual
z-test gives the ‘closed z-test’. Applying the Holm procedure to our adjusted p-values gives
the ‘Holm adaptive test’, while applying the Holm procedure to the usual p-values gives
the ‘Holm z-test’. In our simulation studies, we compare the different methods by looking
at the FWER and the power of the different tests. To keep the comparisons simple, and
as a similar measure to the FWER, we present results for the disjunctive power, which
is the probability of rejecting at least one false null hypothesis. In order to see how the
This article is protected by copyright. All rights reserved
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10 Biometrics, 000 2019
adaptive randomization procedures affect power, we provide comparisons with using equal
randomization in Web Appendix F.5.
4.1 Fully sequential randomization
We first consider a fully sequential response-adaptive trial, as presented in Section 2, with
m = 50 patients allocated to the experimental treatments after the burn-in and n0 = 60/t
patients allocated to the control. In the burn-in period, five patients are allocated to each of
the experimental treatments. We set α = 0.05 and the true control mean µ = 0 for simplicity.
We compare the methods under two randomization schemes, the first being the Type I error
inflator and the second being a Bayesian Adaptive Randomization (BAR) scheme, with full
details given in Web Appendix F.1.
Simulation results : Table 2 gives the results for the type I error inflator randomization
scheme, while Table 3 gives the results for BAR. The auxiliary designs in all scenarios were
simply (m− 1) random draws from a discrete uniform distribution on {1, . . . , t}.
[Table 2 about here.]
[Table 3 about here.]
Looking first at the results for the type I error inflator in Table 2, the closed z-test does
not control the FWER in the scenarios where at least one null hypothesis is false, with an
error rate as high as 10.3% in scenario 2. Applying the Holm procedure to the z-test does
not control the FWER, and actually increases the error rate in some scenarios (1 and 4).
Applying Bonferroni to the z-test also does not control the FWER, as can be seen in scenarios
where all null hypotheses are true. In contrast, both the adaptive closed test and the Holm
adaptive test strongly control the FWER, although they tend to be rather conservative.
The fact that the Bonferroni correction, the use of the closure principle and the Holm
procedure all do not control the FWER may appear surprising at first. The inflation occurs
This article is protected by copyright. All rights reserved
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Familywise error control in multi-armed response-adaptive trials 11
because when using RAR, the usual z-test will no longer be normally distributed under
the null. Therefore the p-values derived from the z-statistics are not guaranteed to be
stochastically larger than or equal to the uniform distribution under the null, which is
required for these methods to work.
As for the power of the different methods, when at least one of the null hypotheses is
true (as in scenarios 2, 5, 6 and 7), the Holm z-test has substantially higher power than the
closed z-test. Indeed, the power more than doubles in all four scenarios, and even more than
triples in scenario 5. This dramatic increase in power demonstrates that in these scenarios,
the closed z-test is not very sensitive. This is because the test statistic for HI will be ‘diluted’
by the contribution from responses belonging to the null hypotheses (Hi)i∈I that are true.
It is only when all of the null hypotheses are false, as in scenarios 3 and 8, that the power
of the closed z-test is reasonable, with a slightly higher power than the Holm z-test.
As for the adaptive tests, the adaptive closed test has a slightly lower power than the
closed z-test for all scenarios, with an absolute decrease of between 4.1% in scenario 5 and
7.5% in scenario 3. However, the Holm adaptive test has a substantially lower power than
the Holm z-test, with the latter having more than double the power. This demonstrates the
high cost in terms of power that controlling the FWER can incur for this randomization
scheme. We return to this issue in Section 4.3.
Turning to the BAR scheme in Table 3, this time all of the methods strongly control the
FWER. All methods are slightly conservative, with the adaptive closed test being generally
the closest to the nominal 5% level. The Bonferroni-corrected z-test is noticeably more
conservative than all the other methods, particularly when there are three treatments. In
terms of disjunctive power, if at least one of the null hypotheses are true, we again see that
the closed tests suffer from reduced power compared to the Holm versions. However, with
BAR the loss of power is less dramatic, with a maximum of a 33% relative decrease in power
This article is protected by copyright. All rights reserved
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12 Biometrics, 000 2019
in scenario 5, but with much smaller decreases in scenarios 2 and 7 for example. This time,
the adaptive closed test has almost the same power as the closed z-test, losing a maximum
of only 1.4% in scenario 8. In addition, the Holm adaptive test and Holm z-test now have
comparable power, with a maximum loss of only 1.9% in scenarios 5 and 7. This indicates
that for BAR schemes, the adaptive tests do not lose out very much in terms of power.
4.2 Block randomization with a fixed control allocation
We now consider block randomized trials with a fixed control allocation, as presented in
Section 3.1. We use the setup of a trial with J = 3 blocks, with sizes (40, 40, 40) for the
experimental treatments and (20, 20, 20) for the control. In the burn-in period, five patients
are allocated to each of the treatments including the control. We set the true control mean
µ = 0, and α = 0.05. We compare the methods under a type I error inflator scheme and a
BAR scheme, with full details given in Web Appendix F.2.
Simulation results : Table 4 gives the results for the type I error inflator randomization
scheme, while Table 5 gives the results for BAR. The auxiliary designs in all scenarios were
simply random draws from a discrete uniform distribution on {1, . . . , t}.
[Table 4 about here.]
[Table 5 about here.]
The results are broadly similar to those for the fully sequential setting presented in
Section 4.1. For the type I error inflator, we see that the closed z-test does not control
the FWER in general (as seen in scenarios 2, 6 and 7), and neither does applying the Holm
procedure to the z-test. The Bonferroni-corrected z-test has an inflated FWER when all
null hypotheses are true, as in scenarios 1 and 4. In contrast, the adaptive tests strongly
control the FWER in all scenarios. However, again this comes at the cost of reduced power.
There is a slight reduction in power between the closed z-test and the closed adaptive test,
This article is protected by copyright. All rights reserved
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Familywise error control in multi-armed response-adaptive trials 13
of between 3− 4% in absolute terms. In scenarios where at least one null hypothesis is true,
the Holm z-test has a much higher power than the Holm adaptive test, with the power more
than doubling in these scenarios, and actually tripling in scenario 6.
As for the BAR scheme, all of the methods strongly control the FWER. This time, for some
scenarios the adaptive closed test basically achieves the nominal 5% level, as in scenarios 2
and 6. When there are three treatments, the Bonferroni-corrected z-test can again be overly
conservative, as in scenarios 6 and 7. In contrast to the fully sequential setting, with block
randomization we see that the adaptive tests actually have the highest power out of all
the methods in all scenarios except scenario 2. When at least one null hypothesis is true,
the Holm adaptive test has the highest power, while when all null hypotheses are false the
adaptive closed test has the highest power. The power gains are small, but demonstrate that
we do not always lose out in terms of power when using the proposed adaptive tests.
Block randomization with an adaptive control allocation: In Web Appendix F.3, we present
a simulation study considering block randomization with an adaptive control allocation, as
presented in Section 3.2. The results are broadly similar to those presented above.
4.3 Summary
In summary, the simulation results show that in the randomization settings considered, our
proposed adaptive tests strongly control the FWER, as would be expected from theory. In
contrast, the various z-tests can all fail to control the error rate, as seen in the results for the
type I error inflator. However, given a more realistic randomization scheme, such as the BAR
schemes we considered, the z-tests achieve strong familywise error control. As for disjunctive
power, we see that when at least one null hypothesis is true, the closed tests suffer a very
large drop in power compared to the Holm versions. This is because of the ‘dilution’ of the
test statistic as mentioned in Section 4.1. However, when all the null hypotheses are true,
then the closed test has the higher power, although the gains are at most modest.
This article is protected by copyright. All rights reserved
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14 Biometrics, 000 2019
The adaptive tests can pay a large price in terms of power when compared with the z-
tests, as seen in the results for the type I error inflator. In Web Appendix F.4, we give an
additional simulation study with two treatments, where the randomization scheme used is
simply a fixed allocation to the experimental treatments but with unequal randomization
probabilities. We show that when the probability of assignment to treatment 2 is low (i.e.
less than 0.2), there is a large drop in the power of the adaptive tests for testing H1. This
explains what is happening with the type I error inflator when δ1 = 0, where in the majority
of trial realisations, apart from the unlikely event that treatment 1 stops early for ‘efficacy’,
the probability of assignment to treatment 2 is zero by design. Hence, the type I inflator is in
fact close to a worst-case scenario for the adaptive tests. However, for adaptive randomization
schemes that implement a restriction on the probability of assignment so that it is above
a minimum threshold (or equivalently a minimal proportion of patients in each treatment
group, we would not expect there to be a substantial loss of power when using the Holm
adaptive test compared with the Holm z-test, particularly in the block randomized setting.
5. Case study
Finally, we illustrate our proposed methodology using an example based on a phase II
placebo-controlled trial in primary hypercholesterolemia (Roth et al., 2012). The purpose
of the study was to compare the effects of using the SAR236553 antibody with high-dose
or lose-dose atorvastatin, as compared with high-dose atorvastatin alone. The primary out-
come was the least-squares mean percent reduction from baseline of low-density lipoprotein
cholesterol (LDL-C). Patients were randomly assigned, in a 1:1:1 ratio, to receive 80 mg of
atorvastatin plus placebo, 10 mg of atorvastatin plus SAR236553, or 80 mg of atorvastatin
plus SAR236553. For convenience, we label these different interventions as the ‘control’, ‘low
dose’ and ‘high dose’ respectively.
In the trial, the observed least-squares mean ± SE percent reduction from baseline in
This article is protected by copyright. All rights reserved
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LDL-C was 17.3 ± 3.5 for the control, 66.2 ± 3.5 for the low dose and 72.3 ± 3.5 for the
high dose. There were N = 31 patients on the control, N = 31 patients on the low dose and
N = 30 patients on the high dose, giving a total of N = 61 patients on the two experimental
doses. We use the observed values from the trial and assume that the distribution of the
least-squares standardized mean percent reduction from baseline of LDL-C is N(17.3/3.5, 1)
for the control, N(66.2/3.5, 1) for the low dose, and N(72.3/3.5, 1) for the high dose.
Now suppose that the trial was carried out as an adaptive block randomized trial with a
fixed control allocation, as described in Section 3.1. Let the trial have J = 3 blocks, with
block sizes (15, 15, 15) for the experimental treatments and (8, 8, 8) for the placebo. In the
burn-in period, 7 patients are allocated to the control and 8 patients are allocated to each
of the experimental doses. Hence, a total of 31 patients are on the control and 61 on the
experimental treatments, as in the original trial. We use the BAR scheme of Section 4.2,
with priors µi,0 = 5 and σ
2
i,0 = 1 (i = 0, 1, 2), while γ = 0.5.
Table 6 shows the results for a simulated trial with the above parameters, where the BAR
scheme allocated 13 patients to the low dose and 32 patients to the high dose after the
burn-in period. This yields the natural weights used in the na¨ıve z-test of n′1 = 21 for the
low dose and n′2 = 40 for the high dose. The natural weight for the control is n0 = 31 by
design. The auxiliary design randomly assigned 44 patients to the low or high dose in a 1:1
ratio, and allocated 21 patients to the low dose and 23 patients to the high dose.
[Table 6 about here.]
The adaptive test statistic is slightly smaller than the z-test statistic for the low dose, while
the converse is true for the test statistics for the high dose. Looking at the adaptive weights
for the burn-in period and the three blocks, we see that for the low dose, the weights for the
low dose decrease for each block while the control weights increase. This pattern is reversed
for the high dose. Given that all the p-values are less than 0.001, using either the z-test or
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the adaptive test we would conclude that adding the SAR236553 antibody to high-dose or
low-dose atorvastatin leads to a statistically significant reduction in LDL-C levels.
6. Discussion
A major regulatory concern over the use of response-adaptive trials in clinical practice has
been ensuring control of the type I error rate. We have proposed procedures that guarantee
strong familywise error control in the following multi-armed trial settings:
(1) Fully sequential response-adaptive trials with a fixed control allocation (where the ran-
domization rule does not depend on the control information);
(2) Block-randomized response-adaptive trials with a fixed control allocation;
(3) Block-randomized response-adaptive trials including an adaptive control allocation.
These procedures are applicable to a large class of RAR rules for settings (2) and (3),
with only some restrictions in setting (1). Hence many Bayesian and ‘optimal’ RAR schemes
proposed in the literature can be used without adjustment, with only the final test statistic
having to be modified. Since our proposed adaptive testing procedures are based on the
conditional invariance principle, they have the additional important flexibility of being valid
when the allocation is changed due to external information (i.e. information other than the
previously observed treatment assignments and patient responses). Such changes might occur
due to safety data, non-compliance or even trial protocol violations.
In practice, to control the FWER we would recommend using the Holm adaptive test.
Importantly, it has a much higher power than the adaptive closed test when at least one of
the null hypotheses are true. As well, it only requires t hypothesis tests as compared with
(2t − 1) hypothesis tests for the adaptive closed test.
Our adaptive tests lead to unequal weightings of patients, which may be controversial.
Indeed, this is a more general issue that can affect the analysis of any flexible adaptive design
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that uses that combination test approach (Burman and Sonesson, 2006). One solution is to
use the so-called ‘dual test’, and reject a hypothesis only if both the adaptive test and the
na¨ıve z-test rejects (Posch et al., 2003), but this can come at the cost of reduced power.
A related problem in practice is explaining the unequal weighting of patients to clinicians,
which would be a fruitful area of further investigation.
As mentioned in Section 2.4, the choice of the allocations in the auxiliary design is meant
to be an approximation of the actual allocations. This choice, while not affecting the control
of the FWER, can affect the power of the resulting adaptive test procedure. If information
is available before the trial begins of a likely ordering of the treatment effects (such as in a
trial testing different doses of a drug), then it might be possible to design ‘optimal’ auxiliary
designs that maximise the expected power of the resulting adaptive test procedure.
We have assumed that the variances of the control and experimental treatments are known.
Fully accounting for unknown variances would add considerable complexity to our approach.
In Web Appendices F.6 and F.7, we show empirically that estimating the variance from the
data (with or without assuming a common variance) does not inflate the FWER when using
the Holm adaptive test, for the simulation scenarios considered in this paper.
Our proposed procedures are designed for normally-distributed outcomes but can be im-
plemented for other types of outcomes through the use of asymptotics. For example, with
survival data one could use the asymptotically standard normal form for the logrank test
statistic. For binary data, a starting point would be to use the asymptotically normal test
statistic for contrasting each treatment arm with the control (Jennison and Turnbull, 2000;
Wason and Trippa, 2014), particularly in the block randomised setting. However, it would be
useful to extend our procedures to work directly with other types of outcomes. This would be
a fruitful yet challenging area for future research, since applying the conditional invariance
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principle in these settings without appealing to asymptotics is likely to be complex, especially
given the form of the usual test statistics (such as Fisher’s exact test).
As mentioned in Section 1, another possible method of controlling the FWER is through
the use of (re)-randomization tests (Simon and Simon, 2011). These tests have the advantage
of being valid under unknown variances, non-normally distributed outcomes and even time
trends associated with the outcome. However, our proposed adaptive testing procedures have
the advantage of being valid under the composite null hypothesis Hi : δi 6 0 (as long as the
weights for the experimental treatments are positive). Also, although it would be interest-
ing to compare randomization tests with our proposed testing procedures, calculating the
randomization p-values using Monte Carlo methods for 105 trial simulations (and repeating
this for each set of parameter values) would be computationally challenging.
Finally, although we did not explicitly consider it in this paper, the adaptive randomization
procedures used could also incorporate covariate information, so that the allocation proba-
bilities vary across patients with different covariates. These covariate-adjusted RAR schemes
are particularly useful when certain characteristics of the patients may be correlated with the
primary outcome (Hu and Rosenberger, 2006). A related setting would be biomaker-guided
response-adaptive trials, such as I-SPY 2.
Acknowledgements
The authors thank the co-editor, associate editor and anonymous referee for their construc-
tive comments. DSR was funded by the Biometrika Trust and the Medical Research Council,
grant code MC UU 00002/6.
References
Brannath, W., Koenig, F., and Bauer, P. (2007). Multiplicity and flexibility in clinical
trials. Pharmaceutical statistics 6, 205–216.
This article is protected by copyright. All rights reserved
 
 
  
 A
cc
ep
te
d
  A
rt
ic
le
 
 
 
 
 
 
 
 
 
 
 
 
Familywise error control in multi-armed response-adaptive trials 19
Burman, C. F. and Sonesson, C. (2006). Are flexible designs sound? Biometrics 62,
664–683.
European Medicines Agency (2002). Points to Consider on Multiplicity Issues in Clinical
Trials. London: CPMP .
Food and Drug Administration (2018). Adaptive Designs for Clinical Trials of Drugs and
Biologics. Available at:
https://www.fda.gov/downloads/drugs/guidances/ucm201790.pdf .
Gutjahr, G., Posch, M., and Brannath, W. (2011). Familywise error control in multi-armed
response-adaptive two-stage designs. Journal of Biopharmaceutical Statistics 21,
818–830.
Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scandinavian
Journal of Statistics pages 65–70.
Hu, F. and Rosenberger, W. F. (2006). The theory of response-adaptive randomization in
clinical trials. John Wiley & Sons.
Jennison, C. and Turnbull, B. (2000). Group sequential methods with applications to
clinical trials. Chapman-Hall/CRC, Boca Raton, FL .
Marcus, R., Peritz, E., and Gabriel, K. R. (1976). On closed testing procedures with
special reference to ordered analysis of variance. Biometrika 63, 655–660.
Park, J. W., Liu, M. C., Yee, D., Yau, C., van ’t Veer, L. J., Symmans, W. F., et al. (2016).
Adaptive Randomization of Neratinib in Early Breast Cancer. The New England
Journal of Medicine 375, 11–22.
Posch, M., Bauer, P., and Brannath, W. (2003). Issues in designing flexible trials. Statistics
in Medicine 22, 953–969.
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., and Stein, E. A. (2012).
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
This article is protected by copyright. All rights reserved
 
 
  
 A
cc
ep
te
d
  A
rt
ic
le
 
 
 
 
 
 
 
 
 
 
 
 
20 Biometrics, 000 2019
The New England Journal of Medicine 367, 1891–1900.
Simon, R. and Simon, N. R. (2011). Using randomization tests to preserve type I error
with response adaptive and covariate adaptive randomization. Statistics & Probability
Letters 81, 767–772.
Wason, J. M., Stecher, L., and Mander, A. P. (2014). Correcting for multiple-testing in
multi-arm trials: is it necessary and is it done? Trials 15, 364.
Wason, J. M. S. and Trippa, L. (2014). A comparison of Bayesian adaptive randomization
and multi-stage designs for multi-arm clinical trials. Statistics in Medicine 33,
2206–2221.
Zhu, H. and Hu, F. (2010). Sequential monitoring of response-adaptive randomized clinical
trials. The Annals of Statistics 38, 2218–2241.
Supporting Information
Additional supporting information may be found online in the Supporting Information
section at the end of the article.
This article is protected by copyright. All rights reserved
 
 
  
 A
cc
ep
te
d
  A
rt
ic
le
 
 
 
 
 
 
 
 
 
 
 
 
Familywise error control in multi-armed response-adaptive trials 21
Table 1
An actual allocation a that is similar to the auxiliary design b. The weights that would be used in the na¨ıve z-test are
n0 = 10, n1 = 4 and n2 = 7.
a = 1 2 2 2 1 2 2 1 2 1 2
b = 1 2 2 1 2 2 1 1 2 1 *
w(1) = 6 6 6 5.16 6 6 4.94 4.94 4.94 4.94 - w
(0)
1 = 9.74, w
(0)
10 = −5.38
w(2) = 6 6 6 7.01 5.74 5.74 7.63 7.63 7.63 7.63 7.63 w
(0)
1 = w
(0)
10 = 9.58
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Table 6
Test statistics, p-values and weights for a simulated block randomized trial using a BAR scheme.
Low dose High dose
z-test statistic 13.76 (p < 0.001) 15.50 (p < 0.001)
Adaptive test statistic 12.21 (p < 0.001) 16.22 (p < 0.001)
Natural weights n′1 = 21, n0 = 31 n
′
2 = 40, n0 = 31
Adaptive weights
w(1) = (30, 28.05, 21.49, 16.43) w(2) = (32, 34.09, 42.68, 46.08)
w(0) = (31, 31.73, 35.91, 42.76) w(0) = (31, 30.43, 28.86, 28.41)
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